Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.20.1
Intangible Assets
6 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 6 – Intangible Assets

 

On January 31, 2016, the Company, entered into an IP agreement with HP to acquire a research license to determine the feasibility of incorporating HP's electro-kinetic display technology in the Company's products. Under the terms of the agreement, the license is to be used for research purposes only, has a purchase price of $200,000 for the technology and a two year closing date. On April 12, 2016 the Company and HP entered into the first amendment to the agreement, which provided that, with respect to the remainder of the purchase price, $75,000 was payable upon completion of the technology transfer and $100,000 was payable upon the first anniversary of the agreement's effective date. The sales agreement entered into with HP concurrently with the first amendment to the agreement allocated $25,000 of the $200,000 purchase price to acquire equipment to be used in the research. On May 1, 2017, the Company and HP entered into the second amendment to the agreement which increased the purchase price for the technology to $375,000 and extended the closing date to January 31, 2020. Of such $375,000, $75,000 is payable upon completion of the technology transfer, $100,000 is payable upon the first anniversary of the agreement's effective date, $100,000 is payable upon the second anniversary of the agreement's effective date and $100,000 is payable upon the third anniversary of the agreement's effective date. On March 10, 2019, the Company and HP entered into the third amendment to the agreement, which extended the closing date to January 31, 2021, enumerated certain intellectual property owned by HP that is not subject to the exclusive license granted to the Company and revised the schedule of fees payable by the Company to HP, such that $100,000 is payable upon the first anniversary of the agreement's effective date, $100,000 is payable upon the second anniversary of the agreement's effective date and $100,000 is payable before April 20, 2019. The parties have subsequently agreed that such payment is not due until December 2019.

 

Under the guidance of ASC 350, Intangibles – Goodwill and Other Intangibles, the Company recorded the research license at the cost to acquire the license. As of March 31, 2019, the Company has paid $275,000 for the transfer of the technology. The remaining $100,000 has been accrued and will be paid over the remaining term of the license. The research license will be amortized over a 10 year useful life.

 

Amounts due under the HP agreement are as follows:

 

Balance due as of March 31, 2016   $ 175,000  
Payment on transfer of technology - April 29, 2016     (75,000 )
Payment on first anniversary of effective date - January 31, 2017     (100,000 )
Balance due as of March 31, 2017     -  
Increase in purchase price of intellectual property - May 1, 2017     200,000  
Payment on second anniversary of effective date - January 31, 2018     (50,000 )
Balance due as of March 31, 2018     150,000  
Payment on July 30, 2018     (50,000 )
Balance due as of  March 31, 2019     100,000  
Balance due as of September 30, 2019   $ 100,000  

 

The carrying amounts related to the research license as of September 30, 2019 and March 31, 2019 were as follows:

 

    September 30,     March 31,  
    2019     2019  
    (Unaudited)        
Research license   $ 375,000     $ 375,000  
Total     375,000       375,000  
Accumulated amortization     (119,793 )     (99,593 )
Research license, net   $ 255,207     $ 275,407  

 

The following table represents the total estimated amortization for the research license for the five succeeding years and thereafter as of September 30, 2019:

 

    Estimated Amortization Expense  
    (Unaudited)  
2020   $ 20,200  
2021     40,290  
2022     40,290  
2023     40,290  
Thereafter     114,137  
Total   $ 255,207  

 

For the three months ended September 30, 2019 and 2018, amortization expense was approximately $10,000 for each period, respectively. For the six months ended September 30, 2019 and 2018, the Company recorded amortization expense of approximately $20,000 for each period, respectively.

 

The Intellectual Property Agreement grants the Company an option to purchase the related assignable patents for a purchase price of $1.4 million and must be exercised at least 60 days prior to the closing date of January 31, 2021. The Company will be responsible for all costs associated with the assignable patents and will pay a royalty of 3.0% of the gross revenues received by the Company and its Affiliates for the sale, rental, license or other disposition of the licensed products. As of September 30, 2019 and the date of this report, the Company has not exercised this option.